Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case
Introduction. Cutaneous melanoma is a highly aggressive malignancy with a significant risk of metastasis. Current treatment strategies include surgical resection, immunotherapy, and targeted therapy directed at mutations in the MAPK/ ERK pathway, particularly BRAF V600E. Despite the efficacy of dual...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2025-07-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/1089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|